1043 related articles for article (PubMed ID: 24185512)
1. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Toy W; Shen Y; Won H; Green B; Sakr RA; Will M; Li Z; Gala K; Fanning S; King TA; Hudis C; Chen D; Taran T; Hortobagyi G; Greene G; Berger M; Baselga J; Chandarlapaty S
Nat Genet; 2013 Dec; 45(12):1439-45. PubMed ID: 24185512
[TBL] [Abstract][Full Text] [Related]
2. Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Robinson DR; Wu YM; Vats P; Su F; Lonigro RJ; Cao X; Kalyana-Sundaram S; Wang R; Ning Y; Hodges L; Gursky A; Siddiqui J; Tomlins SA; Roychowdhury S; Pienta KJ; Kim SY; Roberts JS; Rae JM; Van Poznak CH; Hayes DF; Chugh R; Kunju LP; Talpaz M; Schott AF; Chinnaiyan AM
Nat Genet; 2013 Dec; 45(12):1446-51. PubMed ID: 24185510
[TBL] [Abstract][Full Text] [Related]
3. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
4. The search for ESR1 mutations in breast cancer.
Oesterreich S; Davidson NE
Nat Genet; 2013 Dec; 45(12):1415-6. PubMed ID: 24270445
[TBL] [Abstract][Full Text] [Related]
5. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
7. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Hartmaier RJ; Trabucco SE; Priedigkeit N; Chung JH; Parachoniak CA; Vanden Borre P; Morley S; Rosenzweig M; Gay LM; Goldberg ME; Suh J; Ali SM; Ross J; Leyland-Jones B; Young B; Williams C; Park B; Tsai M; Haley B; Peguero J; Callahan RD; Sachelarie I; Cho J; Atkinson JM; Bahreini A; Nagle AM; Puhalla SL; Watters RJ; Erdogan-Yildirim Z; Cao L; Oesterreich S; Mathew A; Lucas PC; Davidson NE; Brufsky AM; Frampton GM; Stephens PJ; Chmielecki J; Lee AV
Ann Oncol; 2018 Apr; 29(4):872-880. PubMed ID: 29360925
[TBL] [Abstract][Full Text] [Related]
8. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R; Buchwalter G; De Angelis C; Brown M; Schiff R
Nat Rev Clin Oncol; 2015 Oct; 12(10):573-83. PubMed ID: 26122181
[TBL] [Abstract][Full Text] [Related]
9. Activating
Toy W; Weir H; Razavi P; Lawson M; Goeppert AU; Mazzola AM; Smith A; Wilson J; Morrow C; Wong WL; De Stanchina E; Carlson KE; Martin TS; Uddin S; Li Z; Fanning S; Katzenellenbogen JA; Greene G; Baselga J; Chandarlapaty S
Cancer Discov; 2017 Mar; 7(3):277-287. PubMed ID: 27986707
[TBL] [Abstract][Full Text] [Related]
10. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.
Jeselsohn R; Bergholz JS; Pun M; Cornwell M; Liu W; Nardone A; Xiao T; Li W; Qiu X; Buchwalter G; Feiglin A; Abell-Hart K; Fei T; Rao P; Long H; Kwiatkowski N; Zhang T; Gray N; Melchers D; Houtman R; Liu XS; Cohen O; Wagle N; Winer EP; Zhao J; Brown M
Cancer Cell; 2018 Feb; 33(2):173-186.e5. PubMed ID: 29438694
[TBL] [Abstract][Full Text] [Related]
11. The Dysregulated Pharmacology of Clinically Relevant
Andreano KJ; Baker JG; Park S; Safi R; Artham S; Oesterreich S; Jeselsohn R; Brown M; Sammons S; Wardell SE; Chang CY; Norris JD; McDonnell DP
Mol Cancer Ther; 2020 Jul; 19(7):1395-1405. PubMed ID: 32381587
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance: making a point.
McCarthy N
Nat Rev Cancer; 2014 Jan; 14(1):6. PubMed ID: 24285243
[No Abstract] [Full Text] [Related]
13. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
15. A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.
Clusan L; Le Goff P; Flouriot G; Pakdel F
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451133
[TBL] [Abstract][Full Text] [Related]
16. Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer Cells.
Zinger L; Merenbakh-Lamin K; Klein A; Elazar A; Journo S; Boldes T; Pasmanik-Chor M; Spitzer A; Rubinek T; Wolf I
Clin Cancer Res; 2019 May; 25(9):2900-2914. PubMed ID: 30733228
[TBL] [Abstract][Full Text] [Related]
17. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.
Katzenellenbogen JA; Mayne CG; Katzenellenbogen BS; Greene GL; Chandarlapaty S
Nat Rev Cancer; 2018 Jun; 18(6):377-388. PubMed ID: 29662238
[TBL] [Abstract][Full Text] [Related]
18. ESR1 mutations in breast cancer.
Dustin D; Gu G; Fuqua SAW
Cancer; 2019 Nov; 125(21):3714-3728. PubMed ID: 31318440
[TBL] [Abstract][Full Text] [Related]
19. Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.
Jia S; Miedel MT; Ngo M; Hessenius R; Chen N; Wang P; Bahreini A; Li Z; Ding Z; Shun TY; Zuckerman DM; Taylor DL; Puhalla SL; Lee AV; Oesterreich S; Stern AM
Oncology; 2018; 94(3):176-189. PubMed ID: 29306943
[TBL] [Abstract][Full Text] [Related]
20. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
[Next] [New Search]